EXPO Stock Analysis: Exponent | NASDAQ
Engineering & Construction | NASDAQ, USA | Market Cap: 3.995m USD | 12M Return: 23.7% | US30214U1025 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 41.5M
EPS Trend: 81.8%
Qual. Beats: 2
Rev. Trend: 94.7%
Qual. Beats: 5
Warnings
No concerns identified
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Exponent, Inc. (NASDAQ: EXPO) is a science and engineering consulting firm headquartered in Menlo Park, California, founded in 1967 (originally as The Failure Group, rebranded in 1998). The company operates through two segments-Engineering and Other Scientific, and Environmental and Health-delivering technical expertise across disciplines such as biomechanics, biomedical engineering, civil and structural engineering, materials and corrosion engineering, electrical and computer science, human factors, and vehicle engineering, as well as ecological, environmental, and health sciences. Its client base spans a broad range of industries, including chemical, construction, consumer products, energy, food and beverage, government, life sciences, insurance, manufacturing, technology, and transportation. The firms business model centers on deploying highly credentialed scientists and engineers to provide proactive product safety consulting, regulatory support, and reactive litigation support services, often serving as expert witnesses in complex technical disputes. As a mid-cap member of the Industrials sector, Exponent generates revenue primarily through billable hours on consulting engagements rather than product sales, which makes utilization rates and the depth of its technical talent pool key drivers of performance.
- Engineering consulting demand rises on complex product liability litigation
- Environmental and health segment grows amid tightening EPA chemical regulations
- Expert testimony engagements expand as corporate legal spending accelerates
| Net Income: 114.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 4.15 > 1.0 |
| NWC/Revenue: 26.02% < 20% (prev 45.86%; Δ -19.84% < -1%) |
| CFO/TA 0.21 > 3% & CFO 148.7m > Net Income 114.7m |
| Net Debt (-33.5m) to EBITDA (157.8m): -0.21 < 3 |
| Current Ratio: 1.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (48.4m) vs 12m ago -5.89% < -2% |
| Gross Margin: 25.50% > 18% (prev 40.33%; Δ -14.83% > 0.5%) |
| Asset Turnover: 90.62% > 50% (prev 75.04%; Δ 15.59% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.25 (Total Current Assets 353.3m - Total Current Liabilities 181.8m) / Total Assets 693.1m |
| B: 1.03 (Retained Earnings 712.3m / Total Assets 693.1m) |
| C: 0.20 (EBIT TTM 147.5m / Avg Total Assets 727.3m) |
| D: 0.80 (Book Value of Equity 307.9m / Total Liabilities 385.2m) |
| Altman-Z'' = 7.18 = AAA |
| DSRI: 1.00 (Receivables 209.6m/182.0m, Revenue 659.1m/571.4m) |
| GMI: 1.58 (GM 40.33% / 25.50%) |
| AQI: 1.11 (AQ_t 0.29 / AQ_t-1 0.26) |
| SGI: 1.15 (Revenue 659.1m / 571.4m) |
| TATA: -0.05 (NI 114.7m - CFO 148.7m) / TA 693.1m) |
| Beneish M = -2.33 (Cap -4..+1) = BBB |
As of November 12, 2026, the stock is trading at USD 86.20 with a total of 237,057 shares traded. Over the past week, the price has changed by -1.41%, over one month by +21.98%, over three months by +26.68% and over the past year by +23.69%.
Current recommended Stop Loss: 82.90 (which is 3.8% or 1.2 ATR below the current price).
Exponent has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy EXPO.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 90.7 | 5.2% |
P/E Trailing = 36.2155
P/E Forward = 31.5457
P/S = 6.8507
P/B = 12.9781
P/EG = 2.0325
Revenue TTM = 659.1m USD
EBIT TTM = 147.5m USD
EBITDA TTM = 157.8m USD
Long Term Debt = 74.6m USD (estimated: total debt 81.1m - short term 6.53m)
Short Term Debt = 6.53m USD (from shortTermDebt, last quarter)
Debt = 81.1m USD (from shortLongTermDebtTotal, last quarter) (leases 80.7m already included)
Net Debt = -33.5m USD (calculated: Debt 81.1m - CCE 114.7m)
Enterprise Value = 3.96b USD (3.99b + Debt 81.1m - CCE 114.7m)
Interest Coverage Ratio = unknown (Ebit TTM 147.5m / Interest Expense TTM 0.0)
EV/FCF = 28.17x (Enterprise Value 3.96b / FCF TTM 140.6m)
FCF Yield = 3.55% (FCF TTM 140.6m / Enterprise Value 3.96b)
FCF Margin = 21.34% (FCF TTM 140.6m / Revenue TTM 659.1m)
Net Margin = 17.40% (Net Income TTM 114.7m / Revenue TTM 659.1m)
Gross Margin = 25.50% ((Revenue TTM 659.1m - Cost of Revenue TTM 491.0m) / Revenue TTM)
Gross Margin QoQ = 28.33% (prev 20.64%)
Tobins Q-Ratio = 5.72 (Enterprise Value 3.96b / Total Assets 693.1m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 81.1m)
Taxrate = 28.42% (45.5m / 160.2m)
NOPAT = 105.5m (EBIT 147.5m * (1 - 28.42%))
Current Ratio = 1.94 (Total Current Assets 353.3m / Total Current Liabilities 181.8m)
Debt / Equity = 0.26 (Debt 81.1m / totalStockholderEquity, last quarter 307.9m)
Debt / EBITDA = -0.21 (Net Debt -33.5m / EBITDA 157.8m)
Debt / FCF = -0.24 (Net Debt -33.5m / FCF TTM 140.6m)
Total Stockholder Equity = 331.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.77% (Net Income 114.7m / Total Assets 693.1m)
RoE = 34.61% (Net Income TTM 114.7m / Total Stockholder Equity 331.3m)
RoCE = 36.33% (EBIT 147.5m / Capital Employed (Equity 331.3m + L.T.Debt 74.6m))
RoIC = 21.77% (NOPAT 105.5m / Invested Capital 484.9m)
WACC = 6.33% (E(3.99b)/V(4.08b) * Re(6.46%) + D(81.1m)/V(4.08b) * Rd(0.0%) * (1-Tc(0.28)))
Discount Rate = 6.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -87.01 | Cagr: -2.72%
[DCF] Terminal Value 77.88% ; FCFF base≈133.5m ; Y1≈152.3m ; Y5≈221.5m
[DCF] Fair Price = 70.87 (EV 3.34b - Net Debt -33.5m = Equity 3.37b / Shares 47.5m; r=8.35% [WACC [floored]]; 5y FCF grow 14.43% → 2.50% )
EPS Correlation: 81.85 | EPS CAGR: 4.60% | SUE: 1.83 | # QB: 2
Revenue Correlation: 94.68 | Revenue CAGR: 7.67% | SUE: 1.62 | # QB: 5
EPS current Quarter (2027-03-31): EPS=0.86 | Chg30d=+31.30% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=2.57 | Chg30d=+6.50% | Revisions=+50% | GrowthEPS=+24.0% | GrowthRev=+14.3%
EPS next Year (2027-12-31): EPS=2.92 | Chg30d=+7.30% | Revisions=+50% | GrowthEPS=+13.8% | GrowthRev=+8.9%
[Analyst] Revisions Ratio: +70% (up=7, down=0)